Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Sector Gamma AS

Key Points

• Sector Gamma AS reduced its stake in Zimmer Biomet Holdings, Inc. by 22.0%, selling 25,000 shares and owning approximately $8.08 million worth at the end of the reporting period.
• Zimmer Biomet reported a quarterly EPS of $2.07, surpassing analyst expectations and achieving 7.0% year-over-year revenue growth.
• The company announced a quarterly dividend of $0.24 per share, with a dividend yield of 0.9%, payable on October 31st to stockholders of record by September 30th.

Sector Gamma AS trimmed its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 22.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 88,631 shares of the medical equipment provider's stock after selling 25,000 shares during the period. Zimmer Biomet makes up about 2.6% of Sector Gamma AS's portfolio, making the stock its 15th largest holding. Sector Gamma AS's holdings in Zimmer Biomet were worth $8,084,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Forum Financial Management LP lifted its position in Zimmer Biomet by 19.0% in the second quarter. Forum Financial Management LP now owns 5,423 shares of the medical equipment provider's stock worth $495,000 after purchasing an additional 864 shares during the period. Greatmark Investment Partners Inc. lifted its position in Zimmer Biomet by 4.0% in the second quarter. Greatmark Investment Partners Inc. now owns 21,540 shares of the medical equipment provider's stock worth $1,965,000 after purchasing an additional 825 shares during the period. Brookstone Capital Management lifted its position in Zimmer Biomet by 7.5% in the second quarter. Brookstone Capital Management now owns 9,227 shares of the medical equipment provider's stock worth $842,000 after purchasing an additional 644 shares during the period. Citizens & Northern Corp lifted its position in Zimmer Biomet by 2.3% in the second quarter. Citizens & Northern Corp now owns 12,908 shares of the medical equipment provider's stock worth $1,177,000 after purchasing an additional 292 shares during the period. Finally, FNY Investment Advisers LLC lifted its position in Zimmer Biomet by 72.5% in the second quarter. FNY Investment Advisers LLC now owns 690 shares of the medical equipment provider's stock worth $62,000 after purchasing an additional 290 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

ZBH opened at $103.13 on Friday. The stock has a fifty day moving average of $101.86 and a 200-day moving average of $97.71. The firm has a market capitalization of $20.43 billion, a P/E ratio of 25.09, a PEG ratio of 2.39 and a beta of 0.67. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $114.72. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.98 by $0.09. The company had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a $0.24 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. Zimmer Biomet's dividend payout ratio is presently 23.36%.

Insider Activity

In related news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the sale, the senior vice president directly owned 6,833 shares in the company, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.39% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of recent research reports. BTIG Research increased their price objective on Zimmer Biomet from $118.00 to $122.00 and gave the company a "buy" rating in a research report on Monday, October 13th. Rothschild Redb upgraded Zimmer Biomet to a "strong-buy" rating in a research report on Thursday, September 18th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Zimmer Biomet in a research report on Wednesday, October 8th. Redburn Partners set a $130.00 price objective on Zimmer Biomet in a research report on Thursday, September 18th. Finally, Rothschild & Co Redburn initiated coverage on Zimmer Biomet in a research report on Thursday, September 18th. They set a "buy" rating and a $130.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $111.94.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.